Inventor
John Frederick Boylan
Inventor
Bedminster, NJ, US
Overview
Patents· 16 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C07DHeterocyclic compounds17%
C12NMicroorganisms or enzymes10%
A01KAnimal husbandry6%
C12YEnzymes6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
PatentTitleYear
10,940,152Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith202110,646,493Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith202010,619,160Compositions and methods for inhibiting expression of RRM2 genes202010,576,085Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith20209,938,531Compositions and methods for inhibiting expression of RRM2 genes20189,795,607'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20179,737,541'Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith'20179,623,028'Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof'20179,512,124'Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith'20169,428,509'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20169,346,812'Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith'20168,946,176'Compositions and methods for inhibiting expression of RRM2 genes'20158,741,889'Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor'20148,309,299'Combination therapy and method for assessing resistance to treatment'20127,029,892'Serine threonine kinase member, h2520-59'20066,881,542'Serine threonine kinase member, h2520-59'2005Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2005–2006Patents assigned to AMGEN INC (2)· patent assignee history
2005–2006Based in Thousand Oaks, CA, US· patent location history
2012–2015Patents assigned to BOYLAN JOHN FREDERICK (3)· patent assignee history
2012–2021Based in Bedminster, NJ, US· patent location history
2016–2021Patents assigned to SIGNAL PHARM LLC (9)· patent assignee history
2016–2017Patents assigned to SIGNAL PHARMACEUTICAL LLC (3)· patent assignee history
2018–2020Patents assigned to ARROWHEAD PHARMACEUTICALS INC (2)· patent assignee history
2020Based in San Diego, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SIGNAL PHARM LLC | 9 | 2016–2021 |
| BOYLAN JOHN FREDERICKself | 3 | 2012–2015 |
| SIGNAL PHARMACEUTICAL LLC | 3 | 2016–2017 |
| AMGEN INC | 2 | 2005–2006 |
| ARROWHEAD PHARMACEUTICALS INC | 2 | 2018–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| Bedminster, New Jersey, US | 13 | 2012–2021 |
| Thousand Oaks, California, US | 2 | 2005–2006 |
| San Diego, California, US | 1 | 2020 |